Cargando…
Boc5, a Non-Peptidic Glucagon-Like Peptide-1 Receptor Agonist, Invokes Sustained Glycemic Control and Weight Loss in Diabetic Mice
BACKGROUND: Our recent discovery of the substituted cyclobutane Boc5, one of the first non-peptidic agonists at glucagon-like peptide-1 receptors, offers the potential of combining oral availability with full agonism capable of eliciting antidiabetic and antiobesity effects. The present study was ai...
Autores principales: | Su, Haoran, He, Min, Li, Hongmei, Liu, Qing, Wang, Jia, Wang, Yiqian, Gao, Weiwei, Zhou, Ling, Liao, Jiayu, Young, Andrew A., Wang, Ming-Wei |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2483413/ https://www.ncbi.nlm.nih.gov/pubmed/18682834 http://dx.doi.org/10.1371/journal.pone.0002892 |
Ejemplares similares
-
Reversal of Obesity and Insulin Resistance by a Non-Peptidic Glucagon-Like Peptide-1 Receptor Agonist in Diet-Induced Obese Mice
por: He, Min, et al.
Publicado: (2010) -
Effects of glucagon like peptide-1 to mediate glycemic effects of weight loss surgery
por: Salehi, Marzieh, et al.
Publicado: (2014) -
Glycemic Efficacy, Weight Effects, and Safety of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists
por: Handelsman, Yehuda, et al.
Publicado: (2018) -
Weight loss with glucagon‐like peptide‐1 receptor agonists in Bardet‐Biedl syndrome
por: Ganawa, Shawg, et al.
Publicado: (2022) -
Glycemic Control Impact on Body Weight Potential to Reduce Cardiovascular Risk: Glucagon-like peptide 1 agonists
por: Sesti, Giorgio
Publicado: (2011)